AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05166772 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HAIC
Description: Q3W. The total number of HAIC treatments was determined by the investigator based on patient needs. Dose: Oxaliplatin 85 mg / m2 for 2h, Calcium folinate 400 mg / m2 for 2h, 5-FU 400 mg / m2 for 10min, followed by 5-FU 1200 mg / m2 for 23 hours);
Study NCT06445946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Individuals randomized to this arm will receive oral metformin tablets for their Gestational diabetes mellitus treatment.
Study NCT06445946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Individuals randomized to this arm will receive injectable insulin for their Gestational diabetes mellitus treatment.
Study NCT06076837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botensilimab
Description: an Fc-engineered anti-CTLA-4 (cytotoxic T-lymphocyte antigen 4) monoclonal antibody
Study NCT06076837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balstilimab
Description: a human monoclonal immunoglobulin (Ig) G4 (IgG4) antibody, designed to block programmed cell death protein (PD-1) binding by PD-L1 and PD-L2
Study NCT06076837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine Phosphate
Description: an antimalarial agent, that is being used in this patient population to sensitize cancer cells to chemotherapy and leads to anticancer effects through inhibiting autophagy
Study NCT06076837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: a second-generation selective Cyclooxygenase 2 (COX-2) inhibitor, is being used in this patient population to enhance the therapeutic effect of cisplatin by inhibiting the expression of COX-2 as well as inhibit anti-apoptotic gene BCL-2 (B-cell lymphoma 2)
Study NCT06076837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: microtubule inhibitor indicated for the treatment of Metastatic adenocarcinoma of the pancreas as first-line treatment, in combination with gemcitabine
Study NCT06076837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: a nucleoside metabolic inhibitor indicated as a single agent for the treatment of pancreatic cancer
Study NCT06076837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: platinum-based drug indicated for the treatment of advanced cancers
Study NCT05018832 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AlloRx
Description: cultured allogeneic adult umbilical cord derived mesenchymal stem cells
Study NCT01864499 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound measurement of variations in the diameter of the sheath of the optic nerve
Description: pre-and postoperative optic nerve and J2 and J5 for all patients
Study NCT01864499 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasound measurement of variations in the diameter of the sheath of the optic nerve
Description: pre-and postoperative optic nerve and J2 and J5 for all patients
Study NCT06490913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000mg/m2, bid, d1-d14，q3w，1cycle
Study NCT06490913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: 130mg/m2, ivgtt, d1，q3w，1cycle
Study NCT06490913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: cetuximab 500mg/m2, q2w
Study NCT06490913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85mg/m2, d1,q2w
Study NCT06490913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 400mg/m2, d1,q2w
Study NCT06490913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 400mg/m2，d1,q2w
Study NCT05710120 — intervention group
Intervention type: OTHER
Intervention: Hepatitis C Screening Alerts in CHORUS™
Description: ZS Associates developed a machine learning-based model that provides a numeric % chance of returning a positive hepatitis C test for a patient without diagnosed hepatitis C infection. The data used to develop the model included a US-based large scale data source including electronic medical records, medical claims, and pharmacy claims as well as social determinants of health identified from open-source data.~Clinical Health Outcomes Reporting \& Utilization Service (CHORUS™) is a web-based reporting solution that transforms electronic health record data into meaningful information for healthcare providers. CHORUS™ generates a weekly email report that alerts clinics to patients who have a scheduled appt in the coming week and may require attention. In the after period of this study, the alert will identify patients who are eligible to be screened for hepatitis C infection and provide the % chance of returning a positive hepatitis C infection test.
Study NCT05710120 — intervention group
Intervention type: OTHER
Intervention: Standard of Care
Description: CHORUS™ is a service provided to participating clinics and has been used by AIDS Healthcare Foundation for normal healthcare operations for quality improvement and retention in care in recent years. NO alerts identifying patients who are eligible to be screening for hepatitis C infection will be disseminated.
Study NCT05735691 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High-Intensity Treadmill Training
Description: Participants will walk on a treadmill at a speed that produces 70-80% of age-adjusted heart rate reserve or a rating of perceived exertion of 17/20. A total of 30, one hour sessions will be conducted. Training will be conducted in 10 minute bouts, with 2-3 minutes rest between bouts.
Study NCT05735691 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Treadmill Training with Perturbations
Description: Participants will walk on a treadmill and a perturbation of the treadmill will be produced every 20s. Perturbations will randomly occur in the forward, backward, right or left directions, with a perturbation size set to 80% of stability threshold. A total of 30, one hour sessions will be conducted. Training will be conducted in 10 minute bouts with 2-3 minutes rest between bouts.
Study NCT05735691 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Treadmill Training
Description: Participants will walk on a treadmill at a speed that produces 30-40% of age-adjusted heart rate reserve. A total of 30, one hour sessions will be conducted. Training will be conducted in 10 minute bouts, with 2-3 minutes rest between bouts.
Study NCT05735691 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard Treadmill Training
Description: Participants will walk on a treadmill at a speed that produces 30-40% of age-adjusted heart rate reserve. A total of 30, one hour sessions will be conducted. Training will be conducted in 10 minute bouts, with 2-3 minutes rest between bouts.
Study NCT05097703 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Resource
Description: The sleep resource is a card game to be played by children and caregivers as part of their bedtime routine. It includes exercises to help prepare the child for sleep, including deep breathing, mindfulness and light movement. Caregivers will be asked to use the resource for a minimum of three nights a week over a four week period, and complete pre and post outcome measures as well as sleep and resource use diaries for their children
Study NCT06136377 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 177Lu-PSMA-617 PET scan
Description: Patients then begin their first course of treatment an average of 2 months after the 68Ga-PSMA-11 PET scan, with IVR usually divided into a total of 6 courses. During the first course of treatment, patients undergo an initial SPECT scan 5h (±1h) post-injection, and return to the nuclear medicine department for three further SPECT scans, at 24h, 4 days and 8 days post-injection.
Study NCT05019898 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: pupillometry
Description: Step 1: The triage will be carried out by the nurse. The nurse will then perform a self-assessment of the patient's pain using a simple verbal scale.~The nurse will then record the patient's self-assessment of his pain using the numeric scale for pain.~Step 2: Immediately after this first assessment, eligible patients will be approached by the study investigator to be included in the study.~Step 3: If the patient gives informed consent, the study investigator will perform~* The quantification of their anxiety~* An assessment of pain by a NeuroLight videopupillometer (iDmed, Marseille, France) using two dynamic tests, the Pupillary Unrest in Ambient Light (PUAL) and the pupillary light reflex.~Step 4: One hour after the triage, a second pain assessment will be performed. Step 5: The same pupillometry measurements will be taken immediately after the nurse has assessed the pain.
Study NCT05513248 — intervention group
Intervention type: PROCEDURE
Intervention: anatomic lung resection
Description: includes minimally invasive or open lung segmentectomy, lobectomy, bilobectomy and pneumonectomy
Study NCT04831489 — intervention group
Intervention type: RADIATION
Intervention: Imaging
Description: pre and postoperative CT scan of lung
Study NCT06482736 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal Shockwave Therapy
Description: Extracorporeal Shockwave Therapy could reduce the pain of myofascial pain syndrome by pain signal alteration, promoting angiogenesis and increasing perfusion in ischemic tissues induced by sensitization of nociceptors and muscle ischemia.
Study NCT06460402 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ice packing
Description: For both arms, participants will self-administer interventions at home per instructions: ice packs every 2 hours for 48 hours (ice pack arm) or sitz baths 2-3 times daily for 7 days (warm water arm). Standardized supplies and daily logs will be provided. All participants receive standard postop care with analgesics and wound care. Adverse events will be monitored closely. Intervention duration: 48 hours (ice), 7 days (sitz bath). Assessments: baseline, 24/48/72 hours (pain, swelling), 1 week (wound separation). Total study duration per participant: \~1 week from surgery.
Study NCT06460402 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Warm sitz bath
Description: Participants in this arm will receive standard instructions to perform warm water sitz baths at home, starting from the day of surgery and continuing for 7 days postoperatively. They will be advised to take 2-3 sitz baths per day, with each bath lasting for 15-20 minutes. A standard plastic sitz bath basin will be provided to the participants, along with a thermometer to monitor the water temperature. The recommended water temperature range for the sitz baths is 37-40°C (98.6-104°F). Participants will be instructed to keep a daily log recording the number of sitz baths taken, the duration of each bath, and the water temperature. Proper hygiene and wound care instructions will also be provided to prevent infection.
Study NCT06072326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotagliflozin
Description: 200 mg/day as a tablet
Study NCT06072326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambrisentan
Description: 2.5 mg/day as a tablet
Study NCT06072326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambrisentan and Sotagliflozin
Description: 2.5 mg/day Ambrisentan as a tablet in combination with 200 mg/day Sotagliflozin as a tablet
Study NCT04981470 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: baroloop System
Description: vagal nerve stimulation
Study NCT05005806 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega 3 fatty acid
Description: omega 3 fatty acid soft gel
Study NCT05005806 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo soft gel
Study NCT05750875 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loratadine
Description: Participants were given loratadine 10mg, oral, daily, for 4 weeks
Study NCT05750875 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: Participants were given gabapentin 100mg, oral, daily, for 4 weeks
Study NCT05357690 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stellate ganglion block
Description: Ultrasound guided injection into the stellate ganglion performed in the right side of the neck in a sterile fashion.
Study NCT05357690 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Stellate ganglion block
Description: Ultrasound guided injection into the stellate ganglion performed in the right side of the neck in a sterile fashion.
Study NCT05357690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: 10 mL of 0.5% without epinephrine injected in the plane of the right stellate ganglion
Study NCT05357690 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: 10 mL of saline injected in the plane of the right stellate ganglion
Study NCT01722175 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ALPPS surgery
Study NCT01722175 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PVO surgery
Study NCT04712721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-FF58
Description: Single intravenous radiolabeled gallium FF58 injection determined by body weight (3 Megabecquerel (MBq)/Kg (+/- 10%)). Administered dose must not be lower than 150 MBq or higher than 250 MBq.
Study NCT05142475 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor Infiltrating Lymphocytes (TIL)
Description: Adoptive transfer of 1x10\^9-5x10\^10 autologous TILs to patients i.v. in 30-120 minutes.
Study NCT04973436 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical Behavioral Therapy Skills Training
Description: LiveWell: Dialectical behavioral therapy skills training adapted for patients with metastatic lung cancer
Study NCT06281470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WS016 Single Dose(6g)
Description: WS016 6g, to be administered orally as a single dose.
Study NCT06281470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WS016 Single Dose(12g)
Description: WS016 12g, to be administered orally as a single dose.
Study NCT06281470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WS016 Single Dose(24g)
Description: WS016 24g, to be administered orally as a single dose.
Study NCT06281470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WS016 Single Dose(36g)
Description: WS016 36g, to be administered orally as a single dose.
Study NCT06281470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WS016 Single Dose(48g)
Description: WS016 48g, to be administered orally as a single dose.
Study NCT06281470 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SAD matching placebo
Description: Matching placebo, to be administered orally as a single dose.
Study NCT06281470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WS016 Multiple Dose(12g)
Description: WS016 12g, to be administered orally once daily for a consecutive period of 7 days.
Study NCT06281470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WS016 Multiple Dose(24g)
Description: WS016 24g, to be administered orally once daily for a consecutive period of 7 days.
Study NCT06281470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WS016 Multiple Dose(48g)
Description: WS016 48g, to be administered orally once daily for a consecutive period of 7 days.
Study NCT06281470 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MAD matching placebo
Description: Matching placebo, to be administered orally once daily for a consecutive period of 7 days.
Study NCT06098612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C11-SY08
Description: a PET imaging agent
Study NCT05275374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XP-102
Description: XP-102 will be administered orally once or twice daily in a continuous regimen.
Study NCT05275374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib will be administered 2mg orally once a day.
Study NCT04931784 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nitrate
Description: Administration of intra-coronary nitrate before percutaneous coronary intervention
Study NCT04931784 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrate
Description: Administration of intra-coronary nitrate before percutaneous coronary intervention
Study NCT05251181 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline
Description: Normal Saline to be Used as Vehicle in the Phase-III Study to Assess Efficacy of Centhaquine as a Resuscitative Agent for Hypovolemic Shock
Study NCT05251181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Centhaquine
Description: Phase-III Study to Assess Efficacy of Centhaquine as a Resuscitative Agent for Hypovolemic Shock
Study NCT06254911 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV
Study NCT06254911 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transoral Surgery with cervical lymphadenctomy (neck dissection)
Description: Undergo definitive surgical treatment to remove cancer from the tonsil or tongue base combined with removal of the at risk lymph nodes in the neck
Study NCT06254911 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT06254911 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT04222673 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Specialist Suicide Prevention
Description: The intervention will last 3-months, a time frame that overlaps with the typical duration of a VA suicide high risk flag. Meetings will be 30-45 minutes and occur primarily in the community, home, or by telephone. Session content will be rooted in Peer Specialists (PSs) offering nonjudgmental empathic support, active listening, and constructive disclosure and role modeling. A primary focus will be helping patients with flags to identify and strengthen connections with informal supports and participation in activities in their community that will enable them to feel more worthwhile as individuals and hopeful about their future.
Study NCT06277895 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: VOCs
Description: test the end-expiratory gas
Study NCT06277895 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: VOCs
Description: test the end-expiratory gas
Study NCT05358756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SACT-1
Description: Single administartion of 150mg SACT-1
Study NCT05358756 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EDURANT 25Mg Tablet
Description: Single administartion of six EDURANT 25mg tablets (Total 150mg)
Study NCT04796051 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neck orthosis - with posterior cervical weight
Description: The posterior cervical weight orthosis is made of a well-padded adjustable Velcro attached to the end with a two-kilogram weight attached with two durable straps. The device is firmly anchored around the curvature of the jaw and attached with Velcro to the apex of the skull.
Study NCT04796051 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Deep cervical flexors exercise
Description: The participant will lay down in crook lying position, participant's head relaxed on the flat surface. Each participant will passively tuck in his/her chin without activation of superficial cervical muscles. Participants of this group will do 15 repetitions x 3 sets of deep neck flexor exercises every day of the week.
Study NCT05912777 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Scanner
Description: Scanner to be performed by patients
Study NCT05774379 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: virtual reality and fatigue education
Description: virtual reality distraction for 3 days and fatigue education for children
Study NCT05774379 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: fatigue education
Description: fatigue education for children
Study NCT04848558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nipocalimab
Description: Participants will receive IV infusion or SC injection of nipocalimab.
Study NCT04848558 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive IV infusion or SC injection of placebo.
Study NCT05344794 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Enzyme-linked immunosorbent assay
Description: Serum N/OFQ , IL-6 and NE levels were detected.
Study NCT04995055 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JJVC Investigational Multifocal Contact Lens TEST Lens
Description: TEST Lens
Study NCT04995055 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACUVUE® OASYS Multifocal
Description: CONTROL Lens
Study NCT05380011 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Constraint Induced Movement Therapy and Bimanual Task Training
Description: Constraint-Induced Movement Therapy and Bimanual Task Training will be performed. Constraint-Induced Movement Therapy has been shown to improve the uni-manual capacity of the impaired limb as well as improvement in quality and efficiency of movement and greater grasp function, whereas Bimanual Task Training has been shown to improve bimanual task performance, bilateral spontaneous use of affected limb and better bimanual coordination during daily life activities.